HEPION PHARMACEUTICALS, INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
HEPION PHARMACEUTICALS, INC. (HEPA) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2017-11-14
- HEPION PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-09-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $0.00.
- HEPION PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $0.00.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|
| 2017-09-30 | $0.00 10-Q · filed 2017-11-14 | |
| 2016-06-30 | $0.00 10-K · filed 2016-09-28 | |
| 2015-06-30 | $0.00 10-K · filed 2015-09-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |